Program on STIs and HIV Prevention
Jenell Stewart, DO, MPH
Bringing together research methods on rigorous clinical trial, understanding adherence behavior, and community co-design, the current research focus of the STI/HIV Prevention program is on strengthening impact of HIV PrEP through improved access to a variety of methods, doxycycline post-exposure prophylaxis for prevention of bacterial STIs among people who were assigned female sex at birth, and community-based care models for people who use drugs.
Studies
The doxyDOT Study
In an extension of the dPEP Kenya Study (collaboration between Kenya Medical Research Institute, University of Washington, and HHRI), the dPEP Kenya Study Team (Project Director: Jenell Stewart) has launched an evaluation of weekly doxyPEP for prevention of bacterial STIs among women taking HIV PrEP in Kisumu, Kenya utilizing community-based distribution of medications. Launched in August 2024.
doxyDOT study team members at community pharmacy medication distribution site in Kisumu, Kenya
The SHEMobile Study
In collaboration with University of Washington (MPI: Jenell Stewart and Maria Corcorran), the SHEMobile Study aims to evaluate impact of community-based care on HIV PrEP and medications for opioid use disorder uptake and sustained use by using a mobile clinic, that includes point-of-care STI testing, at location and approach co-designed with community advisory board in Seattle, WA. Clinical intervention launched in February 2024.
The foXXy doxy Study (ATN-173/HPTN-115)
The Adolescent Trials Network and HIV Prevention Trials Network (co-protocol chairs: Cheríe Blair and Jenell Stewart) are collaborating to support this RCT of on-demand doxyPEP and weekly doxyPEP compared with standard of care among people ages 13-29 years old across 12 sites in the US. Launching in early 2025.
Foxxy Doxy study sites across the US.